Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 6/2014

THE RESPONSE TO ATYPICAL ANTIPSYCHOTIC DRUGS IN CORRELATION WITH THE CYP2D6 GENOTYPE: CLINICAL IMPLICATIONS AND PERSPECTIVES

LAURA NUSSBAUM1, RALUCA GRĂDINARU2, NICOLETA ANDREESCU2*, VICTOR DUMITRAȘCU3, ANCA TUDOR4, LIANA SUCIU5, RADU ȘTEFĂNESCU2,6, MARIA PUIU2

1.Pedopsychiatry Discipline, Department of Neurosciences, University of Medicine and Pharmacy “Victor Babeș”, Timișoara
2 .Genetics Discipline, Microscopic Morphology Department, University of Medicine and Pharmacy “Victor Babeș”, Timișoara
3 .Pharmacology Discipline, Department of Biochemistry and Pharmacology, University of Medicine and Pharmacy “Victor Babeș”, Timișoara
4 .Discipline of Informatics and Medical Biostatistics, Department of Functional Sciences, University of Medicine and Pharmacy “Victor Babeș”, Timișoara
5 .Clinical Pharmacology Discipline, Faculty of Pharmacology, University of Medicine and Pharmacy “Victor Babeș”, Timișoara
6 .Titu Maiorescu University, School of Medicine, Bucharest

Download Full Article PDF

Atypical antipsychotics are widely used and have been shown to be effective against both positive and negative symptoms of schizophrenia. Through this study we intended to bring to the forefront attention the implications of pharmacogenetics for obtaining the optimum results after antipsychotic treatment in a very sensitive category of patients: children and adolescents. This study was performed between 2009 and 2013 and includes children and adolescents with a diagnosis of schizophrenia or bipolar disorder. 81 patients, aged between 9 and 20 years were included in this study (median age was 15.74±4). The efficacy of the therapy was evaluated through the mean change in the PANSS total scores from baseline- T0, through every timepoint - T1=after 3 months, T2=after 6 months, T3=after 12 months, till endpoint - T4=after 18 months. Genotypes were determined by measuring allele-specific fluorescence using the software for allelic discrimination. Our results, showing statistically significant differences of the clinical score between the groups classified based on the genotype, sustain the use of the pharmacogenetic screening in clinical practice for the personalization of the therapy.